Quarterly report · Q1
4543.TEDINET S100OZIL
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥197.3bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥171.7bn | 2021-04-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥30.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥36.2bn | 2021-04-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥29.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥36.0bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥27.9bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥27.9bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.58T | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.47T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.34T | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥466.9bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥461.4bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.12T | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥874.0bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥856.7bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.12T | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.01T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥874.0bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥209.6bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥186.7bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥200.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥23.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥29.9bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥16.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥14.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥23.1bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥29.61 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥117.45 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥36.9 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥29.6 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥117.38 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥36.87 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 70.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.2% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-06-30 | ¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥198m |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥34.5bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥116.8bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥28.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥46.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥197.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥36.1bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-06-30 | ¥64m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥1.6bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥28.3bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥6.0bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥99.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥29.4bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥43.8bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥6.4bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥171.7bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥41.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 562
| Item | Context | Value | Unit |
|---|---|---|---|
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-06-30 | |
| Type of current period | FilingDateInstant | Q1 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)テルモ株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都渋谷区幡ケ谷二丁目44番１号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of financial position IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of profit or loss IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of comprehensive income IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of changes in equity IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of cash flows IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes reporting entity condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes basis of preparation condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |